Transthyretin (TTR) is one of the many proteins that are known to misfold and aggregate (i.e., undergo amyloidogenesis) in vivo. The process of TTR amyloidogenesis causes nervous system and/or heart pathology. While several of these maladies are associated with mutations that destabilize the native TTR quaternary and/or tertiary structure, wild-type TTR amyloidogenesis also leads to the degeneration of postmitotic tissue. Over the past 20 years, much has been learned about the factors that influence the propensity of TTR to aggregate. This biophysical information led to the development of a therapeutic strategy, termed "kinetic stabilization," to prevent TTR amyloidogenesis. This strategy afforded the drug tafamidis which was recently approved by the European Medicines Agency for the treatment of TTR familial amyloid polyneuropathy, the most common familial TTR amyloid disease. Tafamidis is the first and currently the only medication approved to treat TTR familial amyloid polyneuropathy. Here we review the biophysical basis for the kinetic stabilization strategy and the structure-based drug design effort that led to this first-in-class pharmacologic agent.
Introduction
Transthyretin (TTR) is a tetrameric protein found in the bloodstream at a concentration of ≈ 5 μM, comprising identical 127-amino-acid β-sheet-rich subunits in homozygotes (Fig. 1a) . [2] [3] [4] In heterozygotes, TTR tetramers are made up of variant and/or wild-type subunits combined in a statistical fashion. 5 The established function of TTR in the blood is to transport holoretinol binding protein. 6 While TTR could transport up to 2 Eq of retinol binding protein bound to retinol per TTR tetramer, the average stoichiometry of holoretinol binding protein bound to TTR in the blood is~0.5 Eq. [6] [7] [8] [9] While TTR is the *Corresponding author. Departments of Chemistry and Molecular and Experimental Medicine and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. E-mail address: jkelly@scripps.edu.
Abbreviations used: TTR, transthyretin; T 4 , thyroxine; TBG, thyroid binding globulin; CSF, cerebrospinal fluid; HBP, halogen binding pocket; Aβ, amyloid β; SSA, senile systemic amyloidosis; FAP, familial amyloid polyneuropathy; FAC, familial amyloid cardiomyopathy; CNSA, central-nervous-system-selective amyloidosis; NSAID, nonsteroidal anti-inflammatory drug.
major carrier of thyroxine (T 4 ) in the blood of rodents, utilizing binding sites that are orthogonal to those used for holoretinol binding protein, the T 4 binding sites are effectively unoccupied in humans. 10 There are three T 4 
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These facts, combined with the low T 4 concentration in the blood (0.1 μ M), mean that very little (b 10%) of T 4 in human blood is bound to TTR, and that virtually all (N99%) of the T 4 binding sites in TTR are unoccupied and available for small-molecule binding. This circumstance will be taken advantage of, as described below in our kinetic stabilization strategy, to prevent TTR amyloidogenesis. 10, 13 While TTR is the primary carrier of T 4 in cerebrospinal fluid (CSF), the low concentration of T 4 in CSF leads to the situation being similar to that in the blood in that the vast majority of the T 4 binding sites are unoccupied. 14, 15 The TTR tetramer has two distinct dimer-dimer interfaces, the less stable of which is bisected by the crystallographic 2-fold axis 16 or the z-axis. This interface creates the two identical funnel-shaped T 4 binding sites ( Fig. 1a and b) . 2, 13, 17 The largely hydrophobic T 4 binding sites each have a small inner binding subsite and a larger outer subsite (Fig. 1b) . 1, 13, 18 The T 4 binding sites display positively (Lys15) and negatively (Glu54) charged side chains at their periphery, which complement the zwitterionic structure of T 4 (Fig. 1b) . 1, 3, 13 The three pairs of symmetric hydrophobic depressions that line the T 4 binding site are referred to as the halogen binding pockets (HBPs), so named because they are occupied by the iodine atoms of T 4 (Fig. 1b , dark-red balls). 19, 20 TTR is one of at least 30 different human proteins whose extracellular misfolding and/or misassembly (amyloidogenesis) into a spectrum of aggregate structures is thought to cause degenerative diseases referred to as amyloid diseases, named after the characteristic cross-β-sheet assemblies called amyloid fibrils, which are one of the structures formed from the process of aggregation or amyloidogenesis. [21] [22] [23] Genetic, pharmacologic, pathologic, and biochemical evidence all suggest that human amyloid diseases result from the process of amyloidogenesis. [24] [25] [26] [27] Amyloid can form from intrinsically disordered proteins that lack a welldefined tertiary structure [e.g., the Huntington'sdisease-related exon 1 of the Huntingtin protein or the Alzheimer's-disease-related amyloid β (Aβ) peptide]. 28 In such cases, pathogenesis is often triggered by gene duplication or aberrant posttranslational processing or modifications. [29] [30] [31] Amyloid can also result from the partial unfolding of proteins that normally adopt a well-defined tertiary and/or quaternary structure. [32] [33] [34] [35] Substantial evidence supporting the "conformation change hypothesis" was published in the 1990s, revealing that this category of proteins must partially unfold in order to misassemble into aggregates, including amyloid fibrils. 23, [32] [33] [34] [35] [36] [37] [38] TTR is an example of a protein that has to undergo conformational changes in order to become amyloidogenic. 32, 33 Partial unfolding exposes stretches of largely uncharged hydrophobic residues in an extended conformation that efficiently misassemble into largely unstructured spherical aggregates that ultimately undergo conformational conversion into cross-β-sheet amyloid structures.
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Amyloid Diseases in General
Aging is the most significant risk factor for the development of both sporadic and inherited amyloidoses. 44, 45 Aging-associated deficiencies in stress-responsive signaling probably cause or exacerbate compromised protein homeostasis (or proteostasis), leading to the demise of tissue that does not easily regenerate. [46] [47] [48] [49] Mutations within amyloidogenic proteins, while not absolutely required for human amyloid diseases, often predispose the proteins to amyloidogenesis by destabilizing the nonamyloidogenic native state and sometimes by making the amino acid sequences exposed in partially folded states more amyloidogenic, accelerating the onset of postmitotic tissue degeneration. [50] [51] [52] [53] While much remains to be learned about the molecular underpinnings of why aging is the most important risk factor for the onset of amyloid diseases, it is clear that activation of the heat shock response stress-responsive signaling pathway is markedly protective in worm and mouse models of Alzheimer's disease 47, 49 and in worm models of Huntington's disease. [54] [55] [56] Investigations are under way to sort out the mechanism by which stress-responsive signaling pathways protect against the pathology of amyloidoses.
Sporadic and Inherited TTR Amyloidoses
In humans, both wild-type TTR tetramers and mixed tetramers comprising mutant and wild-type subunits can dissociate, misfold, and aggregate, with the process of amyloidogenesis leading to degeneration of postmitotic tissue. Deposition of wild-type TTR outside and, apparently, ultimately within cardiomyocytes appears to cause senile systemic amyloidosis (SSA), a late-onset sporadic cardiomyopathy that affects as much as 15% of men N80 years of age and a significant number of men as young as 60 years of age. 57, 58 The TTR amyloidoses associated with point mutations in the TTR gene include familial amyloid polyneuropathy (FAP), familial amyloid cardiomyopathy (FAC), and the rare central-nervous-system-selective amyloidoses (CNSA). [59] [60] [61] [62] [63] [64] [65] These patients are almost always heterozygotes, meaning that their tetramers are composed of mutant and/or wild-type TTR subunits, which are generally statistically distributed. 5 These autosomal-dominant inherited (or familial) TTR amyloidoses are typically of earlier onset than the sporadic disease SSA. For example, L55P FAP's onset is at around 20 years of age, 66 whereas V30M FAP symptoms surface around the age of 30 years in the Portuguese population. 59, 65, 67 More than 100 mutations have been associated with familial TTR amyloidosis. 68, 69 Generally, the more destabilizing to the TTR tetramer structure the mutant subunits are, the earlier is the onset of amyloid disease, 50, 70 although, surprisingly, the most destabilized TTR mutants, D18G and A25T, are not the most pathogenic. 71, 72 The pathogenic potential of a TTR variant is determined by a combination of its instability and its cellular secretion efficiency. 70 Highly destabilized TTR mutants are subject to cellular quality control by the proteostasis network and are thus degraded intracellularly by endoplasmic-reticulum-associated degradation mediated by the proteasome. 70 As suggested by their names, FAP first manifests with autonomic and peripheral nervous system symptoms, while FAC presents with cardiac abnormalities; however, many patients have both nervous system symptoms and cardiac symptoms, especially late in the disease course, suggesting that these patients may have a more general postmitotic tissue dysfunction than previously thought. 73 It is not currently understood why a particular mutant prefers a particular site of deposition, with the exception of CNSA-associated TTR mutants, although tissue-selective amyloid deposition probably is influenced by the extracellular matrix unique to that tissue. The CNSA-associated mutants are generally the most destabilizing and lead to central nervous system pathology because the choroid plexus, which synthesizes TTR for secretion into the CSF, is more permissive than the liver, the primary source of TTR in the bloodstream, in terms of secreting highly destabilized and extremely amyloidogenic TTR tetramers. 70 This may be due to the relatively high concentration of T 4 in the choroid plexus, which appears to bind to and stabilize the mutant TTR tetramer in the endoplasmic reticulum by a pharmacologic chaperoning mechanism, affording sufficient stabilization to evade endoplasmicreticulum-associated degradation. 70 Once secreted, the lower extracellular T 4 concentration in the CSF would then favor ligand dissociation, leaving the destabilized TTR tetramer to undergo dissociation, misfolding, and amyloidogenesis.
As mentioned above, the initial pathology caused by some TTR variants comes from their selective destruction of cardiac tissue, while that from other TTR variants comes from compromising the peripheral and autonomic nervous systems; the basis for this initial selectivity in clinical presentation remains unclear. 59, 60, 65, 74, 75 The tissue damage caused by TTR amyloidogenesis appears to stem largely from the toxicity of small, diffusible TTR aggregates, 61, 76 although accumulation of extracellular amyloid may contribute to tissue damage and almost certainly compromises organ structure in the late stages of TTR amyloidoses. 77 In either case, however, we hypothesize that these postmitotic tissues are especially vulnerable to proteotoxicity because these tissues do not readily regenerate. The vulnerability of specific postmitotic tissues to a given TTR mutation may be related to the ineffectiveness of the extracellular matrix and glycosaminoglycans, in particular, in protecting against cytotoxicity. 78, 79 If left unchecked, the amyloidogenesis of most TTR sequences will lead to compromised functions of both the heart (and probably other muscles) and the autonomic and peripheral nervous systems. 59, 60, 65, 74, 75 Ultimately, death occurs within approximately a decade of the onset of symptoms. 59, 74, 75, [80] [81] [82] [83] Emerging Therapeutic Strategies for TTR and Other Amyloidoses
Emerging strategies for treating human amyloid diseases center on reducing the concentration of the amyloidogenic protein or peptide. Since the rate and extent of amyloidogenesis are highly dependent on the concentration of the amyloidogenic peptide and/or the population of the amyloidogenic protein conformations, [84] [85] [86] lowering their concentration offers a potential therapeutic strategy. For example, one strategy to treat Alzheimer's disease is to reduce the production of Aβ, the intrinsically disordered amyloidogenic peptide whose misassembly leads to Alzheimer's disease, by inhibiting β-secretase or Greek letter γ-secretase that together generate the Aβ from the transmembrane amyloid precursor protein. [87] [88] [89] Another strategy is to decrease the concentration of Aβ monomers and oligomers, clearing them by any one of several antibodymediated mechanisms; several clinical trials using monoclonal anti-Aβ antibodies are ongoing †. [90] [91] [92] In light-chain amyloidosis, clonal plasma cells in the bone marrow are eliminated with chemotherapy agents to dramatically reduce the concentration of the amyloidogenic light-chain protein in the blood. [93] [94] [95] [96] [97] Light-chain amyloid disease has been ameliorated in numerous individuals by eliminating the amyloidogenic light chain. [93] [94] [95] [96] [97] The strategy that is currently being practiced to ameliorate FAP associated with mutant TTR aggregation is liver transplantation. 98, 99 In this procedure, a patient's liver that is heterozygous for a diseaseassociated TTR mutation is replaced with one that is homozygous for wild-type TTR. 98 Since TTR is mainly synthesized by the liver, this amounts to a surgical form of gene therapy. While initially effective for~90% of the patients who survive the surgery (liver transplantation of FAP patients reduces the serum concentration of the V30M mutant to b5% of pretransplant levels), 100 ,101 progression of wild-type TTR amyloidosis after about a decade ultimately leads to cardiomyopathy. 98, 102, 103 This surgical gene therapy strategy appears to be less effective for FAP associated with TTR variants other than V30M, probably because these non-V30M patients are generally older when they are transplanted. 102, 104 Combined heart and liver transplantation has been employed for FAC patients, whereas heart transplants have been used to ameliorate SSA. [105] [106] [107] It is important to realize that liver transplantation does not prevent the development of life-threatening arrhythmias in FAP, 102 and, of course, liver and/or heart transplant patients require lifelong immunosuppression, which creates its own challenges.
Emerging additional approaches to lowering the concentration of amyloidogenic TTR include antisense oligonucleotide (Isis Pharmaceuticals) and RNA interference (Alnylam Pharmaceuticals) strategies to lower TTR mRNA levels. 108, 109 Antisense oligonucleotides specific for human TTR mRNA have been shown to inhibit the hepatic synthesis of TTR in mice transgenic for a human amyloidassociated TTR sequence. 108 Parenteral administration of a TTR-specific antisense oligonucleotide, however, had no effect on the expression of TTR by the choroid plexus, which is the source of TTR in the brain. 109 This is likely desirable because there are numerous reports stating that normal TTR levels in the brain appear to be protective against other amyloid diseases such as Alzheimer's disease. 110, 111 However, there is a risk that continued amyloidogenic TTR synthesis in the brain, albeit at lower levels, could put FAP patients at risk for late-onset central-nervous-system-selective TTR amyloidosis.
Antisense oligonucleotides are now being tested clinically by Isis Pharmaceuticals †. Alnylam Pharmaceuticals is using double-stranded RNA (RNAi) directed against TTR mRNA to lower its levels, 112 which in turn lowers the TTR plasma protein concentrations of the FAP-associated variants without affecting the TTR level in the CSF. The TTRtargeting RNAi, when formulated in the appropriate lipid, is quite effective at degrading hepatic TTR mRNA. This approach against TTR amyloidosis is now being explored in human clinical trials †. This strategy is expected to be effective for FAC and SSA, as lowering mutant and/or wild-type TTR should decrease TTR aggregation efficiency thought to cause cardiomyopathy.
The Kinetic Stabilizer Strategy to Ameliorate TTR Amyloidoses: Leveraging an Understanding of the Molecular Mechanism of Aggregation Linked to Pathology
Another strategy for ameliorating amyloidoses caused by the misfolding and misassembly of a protein such as TTR or lysozyme, which normally adopts folded nonamyloidogenic three-dimensional structures, focuses on preventing conformational excursions from the native state or partial denaturation that renders them amyloidogenic (Fig. 2) . 13, 23, [113] [114] [115] [116] Stabilizing the properly folded, nonamyloidogenic conformations of these proteins is considered to be the most conservative approach to treating these maladies because it is still unclear which misfolded or misassembled TTR, light-chain, or lysozyme conformations/quaternary structures lead to proteotoxicity. 61, 76, [117] [118] [119] [120] There is mounting evidence that stopping the process of amyloidogenesis without necessarily clearing the deposited amyloid fibrils 121 is sufficient to stop the degeneration of postmitotic tissue and disease progression. 27 In the case of TTR amyloidogenesis, the tetramer must first dissociate and then the natively folded monomer must undergo partial denaturation in order for the TTR subunits to become aggregation competent. 13, 24, 32, 33, 51, 114, [122] [123] [124] Several mechanisms have been proposed to explain the aggregation of amyloidogenic proteins. 85, 86 In the most widely accepted mechanism, multiple chains of the amyloidogenic protein assemble into an oligomeric nucleus in the rate-limiting step before the rate of amyloid fibril formation becomes substantial. This scenario is referred to as nucleated polymerization (Fig. 3,  top) . 86 For other proteins (e.g., Aβ) whose aggregation appears to cause Alzheimer's disease, rapid oligomerization of the amyloidogenic protein into spherical or amorphous micelle-like assemblies is observed, and these undergo slow conversion into amyloid fibrils in a process associated with a high activation barrier. The latter mechanism is referred to as nucleated conformational conversion and appears to govern Aβ aggregation, at least in vitro (Fig. 3,  middle) . 125 TTR aggregation proceeds by yet a third mechanism referred to as a downhill polymerization reaction. 84 After rate-limiting tetramer dissociation and monomer misfolding, the partially denatured TTR monomers aggregate very efficiently because the misassembled dimer is more stable than the monomer and the misassembled trimer is more stable than the dimer, etc. TTR aggregation does not require nucleus formation, is not amenable to seeding, and is limited only by the relatively low activation barriers of the bimolecular association of misfolded TTR monomers and oligomers, hence the downhill polymerization designation (Fig. 3,  bottom) . 84 After monomeric TTR undergoes partial Fig. 2 . Folding free-energy landscape of an amyloidogenic protein that normally forms a well-folded three-dimensional structure but can also aggregate as a consequence of conformational change (e.g., TTR or lysozyme). Three energy wells are shown: the native state, a partially unfolded amyloidogenic intermediate, and an aggregated state. Conformational excursions convert the native state into the partially unfolded state, which can then aggregate. The stability of the aggregated state depends on the protein concentration. At low protein concentrations, it would be less stable than the native state and, therefore, not substantially populated. As the protein concentration increases, it becomes increasingly stable and will eventually become the most stable state. denaturation, it spontaneously misassembles into a variety of aggregate morphologies, including amyloid fibrils and other structurally diverse aggregates exhibiting varying extents of cross-β-sheet structure (Fig. 4) . 84, 126, 127 Because TTR aggregation is very efficient once the misfolded monomer state is reached, it seems unwise to try to block TTR aggregation after rate-limiting tetramer dissociation.
Tetramer-monomer-unfolded monomer equilibria (Fig. 4) are strongly thermodynamically linked; 128 thus, destabilization of either the tetramer or the folded monomer (and perhaps even the dimer in some mutants) can enhance TTR amyloido-genicity. 50, 51, 53, 71, 72, 122, [127] [128] [129] [130] [131] Generally, the disease-associated TTR mutations characterized to date decrease either tetrameric quaternary structural stability or monomeric tertiary structure stability, or both. 50, 51, 53, [70] [71] [72] 122, 127, [129] [130] [131] The efficiency of TTR amyloidogenesis is dominated by the extent of thermodynamic destabilization, which determines the concentration of TTR adopting an amyloidogenic conformation. TTR tetramer dissociation kinetics, which control the maximal rate of amyloidogenesis, appear to play a less significant role, as some disease-associated mutant homotetramers dissociate more quickly and others dissociate more slowly than wild-type TTR homotetramers.
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The V122I TTR FAC variant is amyloidogenic Fig. 3 . Energy diagrams associated with three distinct mechanisms of protein aggregation. In nucleated polymerization (top), the initial association events are unfavorable until a critical size is reached. The oligomer of this size is referred to as the nucleus. Subsequent steps are favorable, making further growth favorable for oligomers larger than the nucleus. In nucleated conformational conversion (middle), facile initial association steps form amorphous oligomers. Oligomers of a certain size can undergo a ratelimiting conversion step, in which they change from an amorphous structure to a cross-β-sheet fibrillar state. Subsequent steps are favorable, as in the nucleated polymerization. In downhill polymerization (bottom), which is the mechanism by which TTR aggregates, all of the association steps are favorable after the formation of the amyloidogenic monomer, and exhibit low barriers. The aggregates shown are ordered, but they need not be; TTR forms a collection of aggregate structures. Fig. 4 . TTR amyloid cascade. In order for TTR to form amyloid, the tetramer must first dissociate (the rate-limiting step), and then the natively folded monomer must undergo partial denaturation to become competent to misassemble into a variety of aggregate morphologies, including oligomers and amyloid fibrils. Ligands (such as T 4 ; gray and red) stabilize the tetramer and thus prevent amyloidogenesis.
because it forms a relatively unstable tetramer and dissociates rapidly, but its monomers are as stable as those of wild-type TTR. 128, 130 In contrast, the L55P TTR variant forms a stable tetramer, but its monomers are unstable, leading to its efficient amyloidogenesis. 
It is not known what triggers TTR tetramer dissociation and monomer misfolding in vivo.
We hypothesize that tetramer dissociation and monomer misfolding could occur in acidic vesicles that transport TTR to the cell surface or in acidified endocytic vesicles that take TTR into the cell, either by a receptor-mediated process or by macropinocytosis, or the like. 32, 33 Tetramer dissociation does occur at physiological pH, albeit slowly, as evidenced by TTR subunit exchange occurring under physiological conditions with a t 1/2 of~1 day. 5, 114, 126, 127, 132, 133 TTR tetramer dissociation and monomer misfolding in vitro are notably enhanced through the use of acidic denaturing conditions, supporting our hypothesis that an acidified vesicle including endosomes and lysosomes could be responsible for triggering amyloidogenesis in vivo. 32, 33, [134] [135] [136] [137] Just before the Kelly laboratory began developing small molecules that bind to the unoccupied T 4 binding sites in plasma TTR to slow or prevent tetramer dissociation (Fig. 4) (the rate-limiting step of TTR amyloidogenesis), Coelho et al. reported a Portuguese family that appeared to exhibit suppression of TTR amyloid disease phenotypes. 138, 139 This compound heterozygous family expresses the V30M mutation associated with highly penetrant FAP on one allele, yet they do not develop polyneuropathy. Instead of expressing wild-type TTR from their second allele, they express a T119M TTR variant, resulting in the formation of mixed TTR tetramers that exhibit a statistical distribution of V30M and T119M subunits. 5, 24 Subsequent biophysical studies by our laboratory revealed that T119M subunit incorporation into tetramers otherwise composed of V30M subunits proportionately reduces the amyloidogenesis rate under acidic conditions and the rate of tetramer dissociation at neutral pH in urea (Fig. 5a) . 24, 114 Wildtype and T119M TTR homotetramers have very similar thermodynamic stabilities but differ dramatically in their dissociation kinetics. 24, 50, 114 The dissociation rate of the T119M TTR homotetramer is~25-fold slower than the dissociation rate of the wild-type TTR homotetramer, demonstrating that the T119M TTR homotetramer has a much higher dissociation barrier relative to that of the wild-type TTR homotetramer. Hence, T119M subunit inclusion into a tetramer otherwise composed of disease-associated subunits raises the kinetic barrier of tetramer dissociation by destabilizing the dissociative transition state (Fig. 5b) , protecting these individuals from amyloidogenesis and disease by a process referred to as interallelic trans-suppression. 24, 114, 138, 139 The M119 side chains may impart kinetic stability to the TTR tetramer by increasing the surface area of the contacts between the weaker of the two dimerdimer interfaces in the dissociative transition state: the AB/CD interface bisected by the crystallographic 2-fold or z-axis (Fig. 5c) . 16, 17, 140, 141 This interface creates the two symmetric T 4 binding sites. 19, 20 Furthermore, perturbation of this quaternary structural interface by mutagenesis or protein engineering also kinetically stabilizes the tetramer. 16, 17 Collectively, these observations suggest that TTR amyloidogenesis could be suppressed and that amyloid pathology could be ameliorated by kinetically stabilizing the weaker dimer-dimer interface of TTR. We envisioned that small-molecule binding to one or both of the T 4 binding sites should stabilize the AB/CD dimer-dimer interface in the dissociative transition state by simultaneously interacting with the A and C and/or B and D subunits across the weaker dimer-dimer interface of the tetramer, analogous to the hydrophobic bridging interactions enabled by the T119M mutation (Fig. 5c) . 13, 114, 116, 132, 142 The human genetic data mentioned above, along with the corresponding biochemistry, strengthened our resolve to discover small molecules that could bind to the normally unoccupied TTR T 4 binding sites in the blood and prevent amyloidogenesis through kinetic stabilization of the TTR tetramer (Figs. 4 and 5) . 13, 114, 116, 143 This pharmacologic principle was first demonstrated with T 4 (a natural TTR ligand) and 2,4,6-triiodophenol when it was found that they inhibited TTR amyloidogenesis. 116 This proof-of-principle experiment justified a robust screening [144] [145] [146] [147] [148] and structure-based drug design 1, 18 program to find small-molecule TTR ligands that bind tightly and selectively to TTR, kinetically stabilizing the native nonamyloidogenic quaternary structure. 13, 114 It is important that TTR kinetic stabilizers lack thyroid hormone receptor agonism or antagonism while also exhibiting minimal to no binding to the other 4000 or more proteins found in the blood. 13 Poor binding selectivity to TTR would increase the concentration of the kinetic stabilizer required to inhibit TTR aggregation and possibly lead to off-target binding-associated toxicity that would derail a clinical development program.
The Discovery and Design of TTR Kinetic Stabilizers
Over 1000 aromatic small molecules exhibiting structural complementarity to the T 4 binding sites within TTR have been designed and synthesized by taking advantage of ligand 2 -TTR structural information to optimize kinetic stabilizer design. 1, 13, 18, 114, 116, 142, 143, [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] Numerous structurally distinct TTR kinetic stabilizers were identified early in this program using screening approaches, including naturally derived flavonoids, xanthone derivatives, and biaryls, and some of these facilitated the generation of the early ligand 2 -TTR structural information. [144] [145] [146] 148 Structure-based drug design and screening hits guided our synthetic chemistry, affording compounds in multiple structural families, including bisaryloxime ethers, biphenyls, 1-aryl-4,6-biscarboxydibenzofurans, 2-phenylbenzoxazoles, and biphenylamines (Fig. 6a). 1,13,18,114,116,142,143,149-164 Potent compounds have also been identified through halogenation of nonsteroidal anti-inflammatory drugs (NSAIDs) such as salicylic acid, diflunisal, and flufenamic acid. 153, 165, 166 We also recently employed a substructure combination strategy 163 to arrive at potent and selective TTR kinetic stabilizers, wherein we systematically ranked the candidate substructures composing a typical TTR kinetic stabilizer (the two aromatic substructures and the linker) using fibril inhibition potency and plasma TTR binding selectivity data. [159] [160] [161] Of the 92 stilbene and dihydrostilbene candidate kinetic stabilizers predicted to be potent and selective by the substructure combination strategy, nearly all potently inhibit TTR fibril formation, and 17 of these Fig. 6 . The structural diversity of TTR kinetic stabilizer core structures. (a) Line drawings of the structural cores underpinning the 1000 or more TTR kinetic stabilizers synthesized to date. This figure was adapted from Johnson et al. 13 (b) Schematic depiction of the substructure combination strategy to create potent and highly selective TTR kinetic stabilizers. Individual elements of candidate TTR kinetic stabilizers are varied, and the most potent and selective substructures of the candidates are combined to create potent, highly selective TTR kinetic stabilizers. This figure was adapted from Choi et al.
exhibited a binding stoichiometry of N 1.5 (out of a maximum of 2) to plasma TTR while displaying minimal binding to the thyroid hormone receptor (b20% hormone displacement). These potent and selective TTR kinetic stabilizers also rescue cells from the cytotoxic effects of TTR amyloidogenesis. 163 Others have also identified TTR kinetic stabilizers using a variety of the approaches mentioned above. [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] TTR kinetic stabilizers are typically composed of three substructures: two differentially substituted aryl rings connected by a linker (Fig. 6b) . [159] [160] [161] Each ring occupies one of the two subsites of the T 4 binding site in TTR. 1, 13, 18, 163 Substituted aryl rings occupying the outer binding subsite form salt bridges with the Lys15 and/or Lys15′ ɛ-ammonium groups and/or engage in complementary hydrophobic interactions with halogen binding sites 1/1′ and/or 2/2′, whereas the functionalized aromatic rings occupying the inner binding subsite can engage in hydrogen bonds with Ser117 and/or Ser117′ and/or occupy the hydrophobic HBPs 2/2′ and/or 3/3′. 1, 13, 18 These rings either can be linked directly, as in the case of biphenyls, 143, 154 or can be connected through short hydrophobic linkers, 13, 160 as in the case of stilbenes (Fig. 6a) . The linker typically interacts with the hydrophobic side chains of Leu17 and/or Leu17′, Ala108 and/or Ala108′, Leu110 and/or Leu110′, and Val121 and/or Val121′. 160 These complementary interactions between the kinetic stabilizer and TTR combine to differentially stabilize the ground state over the dissociative transition state, making tetramer dissociation extremely slow under physiological conditions (Figs. 4 and 5) . 13, 114 Most TTR kinetic stabilizers bind to the T 4 binding sites with negative cooperativity, apparently resulting from conformational changes within the tetramer upon ligand binding to the first T 4 site. 13, 142, 178 Strikingly, occupancy of only one T 4 binding site is sufficient to impart kinetic stabilization on the entire TTR tetramer. 142 This was demonstrated unequivocally by tethering a kinetic stabilizer, via a linker, to Cys10 in a single monomer of a TTR tetramer. 142 Such a chemically modified TTR tetramer was found to be highly resistant to denaturation and aggregation. These data are enabling in that they allow patients to be treated with lower doses of kinetic stabilizers, doses that are sufficient to occupy one of the two T 4 binding sites. 124 TTR kinetic stabilizers must exhibit high binding affinity and high binding selectivity to plasma TTR over the blood plasma proteome in order to be useful pharmacologic agents. 10, 13, [159] [160] [161] 163 There are N 4000 proteins in blood plasma, including albumin. Albumin binds promiscuously to many small molecules and, by doing so, could prevent TTR kinetic stabilizers from binding to TTR. In a recent review and in the original papers, we provide a comprehensive list of recently synthesized TTR kinetic stabilizers, along with their so-called efficacy scores, which integrate TTR amyloidogenesis inhibitor potency and TTR binding selectivity in plasma. 1, 159, 160, 163 Furthermore, as mentioned above, candidate kinetic stabilizers must not interact with the thyroid hormone receptor, a major concern given the structural similarity of some kinetic stabilizers with triiodothyronine (T 3 ; the primary thyroid hormone) and T 4 (the prohormone). NSAID activity is also undesirable in candidate TTR kinetic stabilizers, as cyclooxygenase inhibition is contraindicated for treating TTR cardiomyopathy patients, who often have impaired renal blood flow. [159] [160] [161] 179 Testing the Kinetic Stabilizer Strategy in a FAP Clinical Trial
The pharmacokinetic and pharmacodynamic properties of most of the small molecules that are potent TTR kinetic stabilizers in vitro and exhibit excellent plasma TTR binding selectivity ex vivo have not been evaluated. To date, only two small molecules have been assessed in animal safety studies and human clinical trials. 27, 180, 181 One of these, diflunisal, is a Foodand-Drug-Administration-approved NSAID that binds to TTR with negative cooperativity (K d1 = 75 nM; K d2 = 1100 nM). 153, 166, 180, 181 Diflunisal exhibits only modest binding selectivity to TTR over all the other plasma proteins and displays modest binding affinity for TTR in vitro. Nevertheless, recent phase I clinical trials showed that diflunisal kinetically stabilizes TTR tetramers in human plasma because of its excellent oral bioavailability and high plasma concentrations after oral dosing (250 mg, twice a day). 180, 181 A placebo-controlled multicenter phase III clinical trial to test the efficacy of diflunisal for the treatment of FAP, FAC, and SSA is currently fully enrolled, with the results expected within the next 2 years †. The enhanced sensitivity of some patients to the gastrointestinal, cardiac, and renal side effects of taking 0.5 g/day diflunisal may limit its applicability to those who can tolerate this dose.
Another small molecule discovered by the Kelly laboratory 143 and developed by FoldRx Pharmaceuticals (acquired by Pfizer in September 2010) was recently shown to slow the progression of FAP in a placebo-controlled double-blind phase II/III clinical trial. 27 Tafamidis [or 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylic acid] (Fig. 7a ) was shown to bind highly selectively to TTR in human plasma and to bind to TTR with negative cooperativity (K d 2 nM and~200 nM) (Bulawa et al.). Tafamidis reaches its EC 50 for preventing TTR fibril formation at a tafamidis/TTR tetramer ratio of b 1, consistent with tafamidis effectively stabilizing TTR when it occupies only one of TTR's two T 4 binding sites. Tafamidis dose-dependently kinetically stabilizes TTR under denaturing conditions (in the presence of 6.5 M urea) and under physiological conditions. According to structural modeling, tafamidis is envisioned to bind to TTR such that it stabilizes the weaker dimer-dimer interface through a combination of specific hydrophobic and electrostatic interactions (Fig. 7b) . Importantly, tafamidis kinetically stabilizes a broad spectrum of TTR variants ex vivo, suggesting a broadly applicable therapeutic for all the TTR amyloidoses (Bulawa et al.).
The 18-month phase II/III clinical trial for tafamidis enrolled N100 patients heterozygous for V30M TTR, the clinically most important FAP-associated mutation (≈10,000 FAP cases worldwide). 27 Treatment with tafamidis (20 mg, once a day) slowed the progression of peripheral and autonomic neuropathies, as measured by a neurologic examination of the lower limbs and nerve conduction studies, among other measures of neuropathy; see the European Medicines Agency Web site ‡ for more details. 27 Tafamidis treatment also improved autonomic nervous system dysfunction and cachexia, as reflected by an increase in the modified body mass index. Finally, tafamidis slowed the decline in the total quality of life, as measured by the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy. 27 Tafamidis was approved by the European Medicines Agency in November 2011 for the treatment of FAP. 2 Approval by the US Food and Drug Administration is currently under consideration. It seems unlikely that the amyloid fibrils in the tafamidis-treated V30M FAP patients were cleared over the course of this trial based on amyloid P component imaging data revealing that amyloid is rarely cleared after liver transplantation. 121 What seems almost certain is that the process of TTR amyloidogenesis is stopped in patients taking tafamidis, although further studies will be required to demonstrate this assertion. The lack of misassembly intermediates in FAP patients with slowed disease progression suggests that the process of TTR amyloidogenesisand not the amyloid fibrils themselves-causes the TTR amyloidoses.
New Directions in the Kinetic Stabilizer Approach
In addition to the abovementioned monovalent TTR kinetic stabilizers, bivalent kinetic stabilizers that simultaneously bind to both T 4 sites have also been developed (Fig. 8a) . Initial work by Green et al. showed that bivalent kinetic stabilizers bind with 1:1 stoichiometry to TTR during tetramer formation within the cell but do not bind to already formed tetramers. 152 More recently, Kolstoe et al. developed bivalent palindromic ligands that bind with high affinity to preformed TTR tetramers under physiological conditions. 167 These bivalent ligands stabilize the tetramer more potently than monovalent ligands. In addition, they preferentially bind mutant TTR over wild-type TTR, perhaps because the inherent instability of mutant TTR allows for easier access to T 4 binding sites in the tetramer. It is not yet clear whether these molecules have suitable TTR plasma binding selectivity, solubility, and appropriate pharmacokinetic and pharmacodynamic properties to serve as clinical candidates.
Covalent kinetic stabilizers of TTR that are more potent inhibitors of amyloidogenesis than their noncovalent counterparts have also recently been reported. 162 Stilbenes (conceived of using structurebased design) that selectively bind to TTR (in preference to the more than 4000 other human plasma proteins) and then react chemoselectively with only one of eight lysine ɛ-amino groups (Lys15) within TTR have been reported. The crystal structure confirms the expected binding orientation of the stilbene substructure and the conjugating amide bond (Fig. 8b) . While these covalent TTR kinetic stabilizers exhibit superior amyloid inhibition potency compared to their noncovalent counterparts in vitro and prevent cytotoxicity associated with the process of amyloidogenesis, their safety, pharmacokinetics, and pharmacodynamics remain to be evaluated.
Perspective and Conclusions
Structure-based drug design principles 1, 13, 18 enabled the efficient design of tafamidis, 143 a highaffinity, highly selective TTR kinetic stabilizer that slows the progression of TTR amyloid disease in FAP patients. 27 This kinetic stabilizer approach for halting aggregation and preventing the degeneration of postmitotic tissue is also being explored in other amyloid diseases as well. For example, small molecules have been used to stabilize the mutant superoxide dismutase-1 associated with familial amyotrophic lateral sclerosis, 182 as well as the β 2 -microglobulin associated with dialysis-related amyloidosis. 183 In addition, camelid antibodies have been employed to stabilize lysozyme to prevent lysozyme amyloidosis. 115 Thus, the kinetic stabilizer strategy, now clinically validated for TTR amyloidosis, has the potential to ameliorate additional degenerative diseases. A modification of this approach-the discovery of small molecules that bind to monomeric, intrinsically disordered protein conformational ensembles, altering their aggregation propensity-is also being explored for Alzheimer's disease. We envision a pharmacologic future wherein synergy in ameliorating the human amyloid diseases is achieved by using small-molecule kinetic stabilizers (or their equivalent), 13 in combination with drugs that lower the concentration of the amyloidogenic protein of interest, 108, 109 and also in combination with drugs that enhance the capacity of the proteostasis network to achieve proteome maintenance. of the numerous appealing kinetic stabilizer candidates that FoldRx could have pursued.
